Member Info for Laura2022

I agree GGG

And also

PYC CEO one of lowest wages on AIM at £70k compared to £200-300k AIM average

= not milking shareholders

Ticor

Yes, the 60min presentation was excellent

Good afternoon

£1.3mln market cap and now £700k+ cash and several newr term catalyst

Following the contract this week , More to come as shown in presentation

91 "warm leads" which means discussions taken place

16 active - ( specifc contract focus)

9 at proposal stage (announcedshortly)....some with Tier 1 companies

Expecting "very strong " H2 and beyond to 2026

Full year revs if hit will be 30% increase on 2024

I cant see if yet ?

Has it appeared today ?

Thanks

Welcome on board, hope you made some on THRU

Yes, what a bizarre twist

Creeping up

Current trading

• The termination of the Bosch contract on 20 February, while disappointing, will have limited financial impact in the low single digit millions of euros for 2025.

• Ceres remains on track to deliver the anticipated savings on restructured and optimised cost base.

• We expect revenue for 2025 will be broadly similar to 2024. We will provide additional guidance on revenue expectations for the full year at our July trading update.

The AR therapeutic market is estimated to reach US$9.2 billion in 2033, driven by the rising prevalence of prostate cancer, the growing adoption of targeted therapies, and the increasing demand for personalised medicine. There are over 46,000 patients in 181 AR clinical studies, with ANGLE targeting key players in the space.

 

·    The DDR therapeutic market was estimated at US$8.2 billion in 2024 and is forecast to grow to US$30.3 billion over the next decade. The complex mechanisms involved in DNA repair and the potential for off-target effects necessitate rigorous preclinical and clinical evaluations. As such, real-time assessment of how the drug impacts the DDR pathway is particularly important during clinical trials

I wonder if this helps Pyc with their "deeper relationship " with DosemeRx mentioned in last months results

DoseMeRx is critical to the nation’s clinicians and patients at a time when the discussion is pointing to vancomycin AUC value in outcomes

Jupiter, FL – March 18, 2025

DoseMe, a leader in model-informed precision dosing (MIPD), has announced a strategic partnership with DaiKnow to advance the adoption of MIPD in India. This collaboration comes at a pivotal moment as India’s scientific research continues to show the value of MIPD as part of day-to-day clinical practice to achieve precise, effective dosing

Please at least read why I unfiltered

Your posting pie chart says everything

Trout

Why are you spending 90% of your time.on PYC and hardly any on FAB and HVO?

Exactly..as with THRU people will pay 100% higher shortly

Great stuff TTS

Sounds lovely VIP

For clarity ive sold some of my 0.7-08p stock for 150%

Hold about 1/3rd still

Profits I'm adding to PYC and TIG

Gluxk

Likely

Board's efforts to maximise shareholder value. We have also received repeated approaches for our Domains, Identity & Software ("DIS") segment, which continues to trade strongly.

Out?

Breaking out from 4 werk resistance

Next target 70-80p?